Clinical trials: Docetaxel
Docetaxel, Solid Tumours
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
The study will be conducted in patients with solid tumors for whom single-agent docetaxel, in the dose of 75 mg/m2, is a suitable treatment option.
- Conditions
- Docetaxel, Solid Tumours, Bioequivalence
- Trial name
- NCT04889599
- Testing
- BH009 (Docetaxel injection), Docetaxel injection
- Where
- 3 sites in India
- Volunteers
- 46 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd